These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18032012)

  • 1. Earlier warning: a multi-indicator approach to monitoring trends in the illicit use of medicines.
    Mounteney J; Haugland S
    Int J Drug Policy; 2009 Mar; 20(2):161-9. PubMed ID: 18032012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The monitoring of drug trends in Australia.
    Shand F; Topp L; Darke S; Makkai T; Griffiths P
    Drug Alcohol Rev; 2003 Mar; 22(1):61-72. PubMed ID: 12745360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reflections on the development and implementation of an early warning system for ecstasy and related drug markets in Australia.
    Kinner SA; Degenhardt L
    Drug Alcohol Rev; 2006 Sep; 25(5):445-9. PubMed ID: 16939940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dependence on psychotropic drugs and substitution treatment: recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997].
    Thirion X; Micallef J; Guet F; Delarozière JC; Arditti J; Huntsman A; Sanmarco JL; Lagier G
    Therapie; 1999; 54(2):243-9. PubMed ID: 10394261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network].
    Modelon H; Frauger E; Laurenceau D; Thirion X; Mallaret M; Micallef J;
    Therapie; 2007; 62(4):337-46. PubMed ID: 17983559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug abuse trends among youth in the United States.
    Banken JA
    Ann N Y Acad Sci; 2004 Oct; 1025():465-71. PubMed ID: 15542750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse consequences of prenatal illicit drug exposure.
    Woods JR
    Curr Opin Obstet Gynecol; 1996 Dec; 8(6):403-11. PubMed ID: 8979011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Illicit drug use and responses in six Pacific Island countries.
    Devaney ML; Reid G; Baldwin S; Crofts N; Power R
    Drug Alcohol Rev; 2006 Jul; 25(4):387-90. PubMed ID: 16854668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adapting the Illicit Drug Reporting System (IDRS) to examine the feasibility of monitoring trends in the markets for 'party drugs'.
    Topp L; Breen C; Kaye S; Darke S
    Drug Alcohol Depend; 2004 Feb; 73(2):189-97. PubMed ID: 14725959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The detection of illicit drugs in oral fluid: another potential strategy to reduce illicit drug-related harm.
    Dyer KR; Wilkinson C
    Drug Alcohol Rev; 2008 Jan; 27(1):99-107. PubMed ID: 18034388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based analysis of the worldwide abuse of licit and illicit drugs.
    Costa e Silva JA
    Hum Psychopharmacol; 2002 Apr; 17(3):131-40. PubMed ID: 12404690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of illicit drug use in Asia and the Pacific.
    Devaney ML; Reid G; Baldwin S
    Drug Alcohol Rev; 2007 Jan; 26(1):97-102. PubMed ID: 17364842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The developmental antecedents of illicit drug use: evidence from a 25-year longitudinal study.
    Fergusson DM; Boden JM; Horwood LJ
    Drug Alcohol Depend; 2008 Jul; 96(1-2):165-77. PubMed ID: 18423900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-level governance: The way forward for European illicit drug policy?
    Chatwin C
    Int J Drug Policy; 2007 Dec; 18(6):494-502. PubMed ID: 18061875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the stability of illicit drug markets: why does it matter?
    Brownstein HH; Taylor BG
    Drug Alcohol Depend; 2007 Sep; 90 Suppl 1():S52-60. PubMed ID: 17175119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of the misuse of prescription drugs by clients of outpatient addiction treatment centres (PHAR-MON, formerly: Ebis-med). Monitoring of medication misuse].
    Küfner H; Rösner S
    Gesundheitswesen; 2008 May; 70(5):305-14. PubMed ID: 18604769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent epidemiologic data on illicit drugs in France: prevalence and health impact of consumption, availability, and product quality].
    Costes JM
    Bull Acad Natl Med; 2002; 186(2):281-94. PubMed ID: 12145836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emergence of potent forms of methamphetamine in Sydney, Australia: a case study of the IDRS as a strategic early warning system.
    Topp L; Degenhardt L; Kaye S; Darke S
    Drug Alcohol Rev; 2002 Dec; 21(4):341-8. PubMed ID: 12537703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The size and mix of government spending on illicit drug policy in Australia.
    Moore TJ
    Drug Alcohol Rev; 2008 Jul; 27(4):404-13. PubMed ID: 18584391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.